# Total Synthesis of Sodium (3S, 4R)-3-[2-(2-Aminothiazol-4-yl)-(Z)-2methoxviminoacetamido]-4-methoxvmethyl-2-azetidinone-1-sulfonate from D-Aspartic Acid

Bong Young Chung\*, Jin Yeon Kim, Cha Soo Nah, Kee Jong Han, and Jong Ok Park

Department of Chemistry, Korea University, Seoul 136-701. Received January 27, 1992

Sodium (3S, 4R)-3-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-4-methoxymethyl-2-azetidinone-1-sulfonate (2) was synthesized in fourteen steps from D-aspartic acid. Starting from D-aspartic acid, (3S, 4R)-3-amino-1-t-butyldimethylsilyl-4-methoxymethyl-2-azetidinone (12) was synthesized in ten steps. Acylation of the amino group of 12 with 2-amino-α-(methoxyimino)-4-thiazoleacetic acid, desilylation, sulfonation, and ion exchange afforded sodium (3S, 4R)-3-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-4-methoxymethyl-2-azetidinone-1-sulfonate (2). This new β-lactam compound 2 showed low antibacterial activities.

#### Introduction

In the preceding paper, we have described the total synthesis of sodium (3R, 4S)-3-\[2-(2-aminothiazol-4-vl)-(Z)-2-methoxyiminoacetamido]-4-methoxymethyl-2-azetidinone-1-sulfonate (1), which is structurally related to aztreonam<sup>2</sup> and carumonam<sup>3</sup>. In this paper, we wish to report the total synthesis of its antipodal compound, sodium (3S, 4R)-3-[2-(2aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-4-methoxymethyl-2-azetidinone-1-sulfonate (2), from D-aspartic acid.

#### Results and Discussion

For the manipulation of the (3S, 4R)-configuration in the title compound 2, D-aspartic acid was chosen as the starting material. Dehydration of D-aspartic acid with PCl<sub>3</sub> afforded D-aspartic anhydride hydrochloride (3), which was transformed regioselectively into α-benzyl D-aspartate (4) with benzyl alcohol. N-Benzylation of the compound 4 with benzyl bromide produced α-benzyl N-benzyl-D-aspartate (5) in 70% yield. Cyclization of this β-amino acid 5 with O-ethyl phosphorodichloridate4 in CH3CN (0.01 M) at room temperature afforded (R)-1-benzyl-4-benzyloxycarbonyl-2-azetidinone (6) in 90% yield.

Reduction of the benzyloxycarbonyl group of the compound 6 with sodium borohydride and methylation of the resulting hydroxymethyl group with CH<sub>3</sub>I in the presence of Ag<sub>2</sub>O afforded (R)-1-benzyl-4-methoxymethyl-2-azetidinone (8) in 60% overall yield. Due to the reasons discussed in the preceding paper<sup>1</sup>, the benzyl group of the compound 8 was removed with lithium in liquid ammonia and reprotected with t-butyldimethylsilyl group to give (R)-1-t-butyldimethylsilyl-4methoxymethyl-2-azetidinone (10) (see Secheme 1).

Introduction of the azido group at the 3-position of the compound 10 with LDA and tosyl azide afforded (3S, 4R)-3azido-1-t-butyldimethylsilyl-4-methoxymethyl-2-azetidinone (11) in 60% yield. The trans configuration between the C-

Scheme 2

3 and C-4 protons of the compound 11 was confirmed by the coupling constants of 3.0 Hz determined from its 2D-COSY NMR spectral data. The azido group of compound 11 was reduced by hydrogenation over 10% Pd/C and acylated with (Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetic acid in the presence of 1-methanesulfonyloxy-6-trifluoromethylbenzotriazole to produce (3S, 4R)-3-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido \rac{1}{-1-t}-butyldimethylsilyl-4methoxymethyl-2-azetidinone (13) in 60% yield. Desilylation of 13 with tetra-n-butylammonium fluoride, N-sulfonation with sulfur trioxide-pyridine complex and ion exchange with Dowex-50W (Na+ form) afforded the title compound, sodium (3S, 4R)-3-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-4-methoxymethyl-2-azetidinone-1-sulfonate (2), in 66% yield (see Scheme 2).

The *in vitro* antibacterial activities of the title compound **2** were also tested against 20 representative strains, but its MIC values were quite high compared to those of cefotaxime.

## Experimental

General comments and synthetic procedures of the L-series of the following compounds are described precisely in the preceding paper.<sup>1</sup>

- **D-Aspartic anhydride hydrochloride (3)** was prepared from D-aspartic acid as white solid (85% yield): mp. 142-144°C; IR (KBr) 1820, 1790 cm $^{-1}$ ;  $^{1}$ H-NMR (DMSO-d<sub>6</sub>)  $\delta$  2. 33-3.10 (m, 2H), 3.80-4.37 (m, 1H), 7.90-9.00 (brd, 2H).
- α-**Benzyl D-aspartate (4)** was prepared as white solid from compound 3 and benzyl alcohol (75% yield): mp. 174°C (lit.<sup>5</sup> 175-176°C);  $[α]_D^{26}+0.30°$  (c 0.85, 1 N NaOH); IR (KBr) 3400-2400, 1740 cm<sup>-1</sup>; <sup>1</sup>H-NMR (TFA-d) δ 3.37 (d, J=4.5 Hz, 2H), 4.60 (t J=4 Hz, 1H), 5.20, 5.40 (ABq, J=12 Hz, 2H), 7.30 (s, 5H).
- α-Benzyl N-benzyl-D-aspartate (5) was prepared from compound 4, benzyl bromide and triethylamine as colourless solid (70% yield): mp. 127-129°C;  $[α]_D^{26}+30.8$ ° (c 0.27, CH<sub>3</sub> CN); IR (KBr) 1720 cm<sup>-1</sup>;  $^1$ H-NMR (TFA-d) δ 3.36 (d, J=5 Hz, 2H), 4.34 (t, J=5 Hz, 1H), 4.40 (s, 2H), 5.47, 5.63 (ABq, J=12 Hz, 2H), 7.23 (s, 5H), 7.26 (s, 5H).
- (R)-1-Benzyl-4-benzyloxycarbonyl-2-azetidinone (6) was prepared as colorless oil by cyclizing compound 5 with O-ethyl phosphorodichloridate in acetonitrile (90% yield):  $[\alpha]_D^{26} + 33.7^{\circ}$  (c 0.71, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) 1760 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.90-3.07 (m, 2H), 3.78 (t, J=4 Hz, 1H), 3.90, 4.75 (ABq, J=14 Hz, 2H), 5.03 (s, 2H), 7.16 (s, 5H), 7.26 (s, 5H).
- (R)-1-Benzyl-4-hydroxymethyl-2-azetidinone (7) was obtained as white solid from azetidinone 6 (80% yield): mp. 83-85°C;  $[\alpha]_D{}^{26}-33.5°$  (c 2.15, CH<sub>2</sub>Cl<sub>2</sub>); IR (CHCl<sub>3</sub>) 3350, 1740 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.70 (d, J=2 Hz, 2H), 3.43-3.82 (brd, 3H), 3.72 (s, 1H), 4.09, 4.58 (ABq, J=14 Hz, 2H), 7.25 (s, 5H).
- (R)-1-Benzyl-4-methoxymethyl-2-azetidinone (8) was prepared as yellowish oil by methylation of compound 7 with methyl iodide in the presence of silver oxide (75% yield):  $[\alpha]_D^{25}-24.0^\circ$  (c 1.41, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) 1750 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) 8 2.60-2.80 (m, 2H), 3.03 (s, 3H), 3.20 (brd s, 2H), 3.30-3.67 (m, 1H), 4.33, 4.73 (ABq, J=14 Hz, 2H), 7.03 (s, 5H).
- (R)-4-Methoxymethyl-2-azetidinone (9) was prepared as colourless oil by debenzylation of the compound 8 with lithium in liquid ammonia (75% yield):  $[\alpha]_D^{25} 7.4^{\circ}$  (c 0.26, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) 3370, 1760 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  2.66-3.01 (m, 2H), 3.35 (s, 3H), 3.52 (brd s, 2H), 3.41-4.02 (m, 1H), 7.15-7.53 (brd, 1H).
- (R)-1-t-Butyldimethylsilyl-4-methoxymethyl-2-azeti-dinone (10) was prepared as colourless oil from compound 9 (quantitative yield):  $[\alpha]_D^{25}-16.0^{\circ}$  (c 1.14, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) 1775 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.30 (s, 6H), 1.00 (s, 9H), 2.88, 3.06 (dd, J=3 Hz, 5 Hz, 2H), 3.40 (s, 3H), 3.53 (brd s, 2H), 3.40-3.90 (m, 1H).
- (3S, 4R)-3-Azido-1-t-butyldimethylsilyl-4-methoxymethyl-2-azetidinone (11) was prepared as an oil from compound 10, LDA and tosyl azide (60% yield):  $\left[\alpha\right]_D^{27}$  60.6°

- (c 0.35, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) 2250, 1788 cm<sup>-1</sup>,  $^{1}$ H-NMR (CDCl<sub>3</sub>) 8 0.22 (s, 3H), 0.23 (s, 3H), 0.97 (s, 9H), 3.38 (s, 3H), 3.43-3.58 (m, 2H), 3.63-3.80 (m, 1H), 4.43 (d, J=3 Hz, 1H).
- (3S, 4R)-3-Amino-1-t-butyldimethylsilyl-4-methoxymethyl-2-azetidinone (12) was obtained as an oil from compound 11 by hydrogenation over 10% Pd/C:  $[\alpha]_D^{27}$ -37.9° (c 0.29, CHCl<sub>3</sub>); IR (CHCl<sub>3</sub>) 3380, 1755 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.23 (s, 6H), 0.93 (s, 9H), 2.10 (s, 2H), 3.34 (s, 3H), 3.49 (brd s, 2H), 3.80-4.05 (m, 1H), 4.55-4.80 (brd, 1H).
- (3S, 4R)-3-[2-(2-Aminothiazol-4-yl)-(Z)-2-methoxy-iminoacetamido]-1-*t*-butyldimethylsilyl-4-methoxy-methyl-2-azetidinone (13) was prepared as yellowish solid from azetidinone 12 and 2-amino-α-(methoxyimino)-4-thiazol-eacetic acid in the presence of FMS (71% yield): mp. 45-47°C;  $[α]_D^{25}-16.7^\circ$  (c 4.87, CH<sub>3</sub>OH); IR (CH<sub>2</sub>Cl<sub>2</sub>) 3455, 3325, 1755, 1680 cm<sup>-1</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub> and DMSO-d<sub>6</sub>) δ 0.23 (s, 6H), 1.02 (s, 9H), 3.35 (s, 3H), 3.67 (brd s, 2H), 3.90 (s, 3H), 3.91-4.33 (brd, 1H), 4.80-5.10 (brd, 1H), 6.83 (s, 1H), 8.70-8.90 (brd, 1H).
- (3S, 4R)-3-[2-(2-Aminothiazol-4-yl)-(Z)-2-methoxy-iminoacetamido]-4-methoxymethyl-2-azetidinone (14) was prepared as white solid from compound 13 by desilylation with tetrabutylammonium fluoride (83% yield): mp. 125-127°C;  $[\alpha]_D^{25}$ -37.6° (c 0.03, CH<sub>3</sub>OH); IR (KBr) 3430, 3300, 1782, 1698 cm<sup>-1</sup>; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)  $\delta$  3.45 (s, 3H), 3.51 (brd s, 2H), 3.55-3.85 (brd, 1H), 3.92 (s, 3H), 4.55-4.85 (brd, 1H), 6.93 (s, 1H), 9.10-9.31 (brd, 1H).
- Sodium (3S, 4R)-3-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-4-methoxymethyl-2-azetidinone-1-sulfonate (2) was prepared as solid from compound 14 by N-sulfornation with sulfur trioxide-pyridine complex followed by ion exchange with Dowex-50W (Na<sup>+</sup> form) (80% yield): IR (KBr) 3440, 3320, 1775, 1705 cm<sup>-1</sup>;  $^{1}$ H-NMR (DMSO -d<sub>6</sub> and TFA-d)  $\delta$  3.58 (s, 3H), 3.73 (brd s, 2H), 3.88 (s, 3H), 3.95-4.15 (brd, 1H), 4.55 (dd, J=3 Hz, 2 Hz, 1H), 6.93 (s, 1H), 9.15-9.40 (brd, 1H).

**Antibacterial Activities** of the compounds **2** were also tested as described in the preceding paper<sup>1</sup> but the MIC values were very high.

**Acknowledgement.** The financial supports from the Korea Science and Engineering Foundation and the Organic Chemistry Research Center sponsored by KOSEF, and the measurement of the *in vitro* biological activities by the Korea Research Institute of Chemical Technology are gratefully acknowledged.

## References

- B. Y. Chung, C. S. Nah, J. Y. Kim, H. Rhee, and Y. C. Cha, Bull. Korean Chem. Soc., 13, 311 (1992).
- 2. R. B. Sykes, D. P. Bonner, K. Bush, and N. H. Georgopa-padakou, *Antimicrob. Agents Chemother.*, 21, 85 (1982).
- S. Kishimoto, M. Sendai, S. Hashiguchi, M. Tomimoto, Y. Satoh, T. Matsuo, M. Kondo, and M. Ochiai, *J. Antibiot.*, 36, 1421 (1983).
- B. Y. Chung, C. W. Kim, S. Kim, J. M. Lee, and J. Namkung, *Tetrahedron Lett.*, 31, 2905 (1990).
- J. Kovacs, H. N. Kovacs, and R. Ballina, J. Am. Chem. Soc., 85, 1839 (1963).